
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Two New Dilaudid Dosage Forms Are Available From Knoll
WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)-- Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now available from Knoll Pharmaceutical Company.
WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)--Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now availablefrom Knoll Pharmaceutical Company.
The 8 mg tablets allow easy titration to a higher hydromorphonedose and are more convenient for patients currently taking twoDilaudid 4 mg tablets per dose, the manufacturer said.
Dilaudid-5 Oral Liquid is designed for patients who have difficultyswallowing solid medications. One teaspoon contains 5 mg of hydromorphoneper 5 mL. The liquid is alcohol-free, colorless, unflavored, andcan be mixed with fruit juice, according to Knoll.
In addition, Knoll is making available a pocket guide "Strategiesfor Cancer Pain Management," written by Ada Rogers, RN, researchassociate and clinical coordinator of the Pain Research Group,Memorial Sloan-Kettering Cancer Center.
The guide contains general information on opioid use in cancerpain, as well as specific dosing information on Dilaudid, includinga dose conversion chart. Call 201-575-5656 (9 am to 5 pm EST)for free copies.
Articles in this issue
about 31 years ago
First Results of Avicidin Trialsabout 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesabout 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicabout 31 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationabout 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseaseabout 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialabout 31 years ago
Ultrasound Breast Screens Useful in Selected Womenabout 31 years ago
New Roles Forecast for Endocrine Therapyabout 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsabout 31 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of DevelopmentRelated Content


TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer




















































